Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Pain and Headache Reports
Erschienen in: Current Pain and Headache Reports 5/2019

01.05.2019 | Other Pain (A Kaye and N Vadivelu, Section Editors)

CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review

verfasst von: Ivan Urits, Mark R. Jones, Kyle Gress, Karina Charipova, Jacob Fiocchi, Alan D. Kaye, Omar Viswanath

Erschienen in: Current Pain and Headache Reports | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of the following review is to summarize the most recent understanding of migraine pathophysiology, as well as of basic and clinical science pharmacologic literature regarding the development of calcitonin gene receptor peptide (CGRP) antagonists as a novel therapeutic modality for the treatment of migraine headaches. A review is provided of erenumab, the first of its class FDA approved CGRP antagonist.

Recent Findings

Despite its high prevalence, the occurrence and treatment of migraine headaches is poorly understood. Erenumab and CGRP antagonists as a whole significantly reduce the average number of migraine days experienced in migraine sufferers.

Summary

CGRP antagonists appear to significantly improve treatment outcomes in patients who suffer from episodic and chronic migraines. Erenumab is the first CGRP antagonist to be FDA approved for public use; however, further development of biologics in this class is underway.
Literatur
1.
Bajwa ZH, Wootton RJ, Wippold FJ II. Evaluation of headache in adults. UpToDate. 2018.
2.
Society IH. The International Classification of Headache Disorders, 3rd edn. 2018.
3.
Cutrer FM, Bajwa ZH. Pathophysiology, clinical manifestations, and diagnosis of migraine in adults. UpToDate. 2017.
4.
Russo A. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533–52.CrossRef
5.
Giffin N, Lipton R, Silberstein J, Olesen S, Goadsby P. The migraine postdrome: an electronic diary study. Neurology. 2016;87:309–13.CrossRef
6.
Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001;98:4687–92.CrossRef
7.
Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004;113:1447–55.CrossRef
8.
Karatas H, Erdener S, Gursoy-Ozdemir Y, Lule S, Eren-Koçak E, Sen Z, et al. Spreading depression triggers headache by activating neuronal Panx1 channels. Science. 2013;339:1092–5.CrossRef
9.
Lipton R, Stewart W, Diamond S, Diamond M, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–57.CrossRef
10.
Lipton R, Bigal M, Diamond M, Freitag F, Reed M, Stewart W, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–9.CrossRef
11.
Stewart W, Wood C, Reed M, Roy J, Lipton R, Group AA. Cumulative lifetime migraine incidence in women and men. Cephalagia. 2008;28:1170–8.CrossRef
12.
Martin V, Behbehani M. Toward a rational understanding of migraine trigger factors. Med Clin North Am. 2001;85:911–41.CrossRef
13.
Kelman L. The triggers or precipitants of the acute migraine attack. Cephalagia. 2007;27:394–402.CrossRef
14.
Bajwa ZH, Smith JH. Preventive treatment of migraine in adults. UpToDate. 2018.
15.
Goadsby P, Lipton R, Ferrari M. Migraine—current understanding and treatment. N Engl J Med. 2002;346:257–70.CrossRef
16.
Bajwa ZH, Smith JH. A cute treatment of migraine in adults. UpToDate. 2018.
17.
Breeze A, Harvey T, Bazzo R, Campbell I. Solution structure of human calcitonin gene-related peptide by 1H NMR and distance geometry with restrained molecular dynamics. Biochemistry. 1991;30:575–82.CrossRef
18.
Sexton P, Christopoulos G, Christopoulos A, Nylen E, Snider R Jr, Becker K. Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. Crit Care Med. 2008;36:1637–40.CrossRef
19.
Muddhrry PK, Ghatki MA, Spokks RA, Jonhs PM, Pierson AM, Hamid Q, et al. Differential expression of α-CGRP and β-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience. 1988;25:195–205.CrossRef
20.
Poyner D, Sexton P, Marshall I, Smith D, Quirion R, Born W, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharm Rev. 2002;54:233–46.CrossRef
21.
Zhang Z, Winborn C, Marquez de Prado B, Russo A. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci. 2007;27:2693–703.CrossRef
22.
Archbold J, Flanagan J, Watkins H, Gingell J, Hay D. Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development. Trends Pharmacol Sci. 2011;32:591–600.CrossRef
23.
Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57:47–55.CrossRef
24.
Walker CS, Conner AC, Poyner DR, Hay DL. Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol Sci. 2010;31:476–83.CrossRef
25.
Walker C, Sajedeh E, Bower RL, Wilderman A, Insel PA, Edvinsson L, et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol. 2015;2:595–608.CrossRef
26.
Walker C, Hay D. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin andamylin receptors? Br J Pharmocol. 2013;170:1293–307.CrossRef
27.
McCulloch J, Uddman R, Kingman T, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A. 1986;83:5731–5.CrossRef
28.
Goadsby P, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183–7.CrossRef
29.
Goadsby P, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48–56.CrossRef
30.
Lassen L, Haderslev P, Jacobsen V, Iversen H, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalagia. 2002;22:54–61.CrossRef
31.
Lennerz J, Rühle V, Ceppa E, Neuhuber W, Bunnett N, Grady E, et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008;507:1277–99.CrossRef
32.
Russo A, Kuburas A, Kaiser E, Raddant A, Recober A. A potential preclinical migraine model: CGRP-sensitized mice. Mol Cell Pharmocol. 2009;1:264–70.
33.
Coull J, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005;438:1017–21.CrossRef
34.
Souslova V, Cesare P, Ding Y, Akopian A, Stanfa L, Suzuki R, et al. Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature. 2000;407:1015–7.CrossRef
35.
MacKenzie ET, Edvinsson LSB. Functional bases for a central serotonergic involvement in classic migraine: a speculative view. Cephalalgia. 1985;5:69–781.CrossRef
36.
Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009;49:1258–66.CrossRef
37.
•• Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123–32 Important STRIVE phase 3 trial demonstrating efficacy of erenumab for the prevention of episodic migraines. CrossRef
38.
Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80:193–9.CrossRef
39.
Hostetler ED, Joshi AD, Sanabria-Bohorquez S, Fan H, Zeng Z, Purcell M, et al. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther. 2013;347:478–86.CrossRef
40.
Pellesi L, Guerzoni S, Pini LA. Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev. 2017;6:534–47.CrossRef
41.
Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S, et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. Informa UK Ltd. 2018;21:666–75.CrossRef
42.
Vu T, Ma P, Chen JS, de Hoon J, Van Hecken A, Yan L, et al. Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects. Pharm Res Pharm Res. 2017;34:1784–95.PubMed
43.
de Hoon J, Van Hecken A, Vandermeulen C, Yan L, Smith B, Chen JS, et al. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther. 2018;103:815–25.CrossRef
44.
Giamberardino MA, Affaitati G, Costantini R, Cipollone F, Martelletti P. Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. J Pain Res. 2017;10:2751–60.CrossRef
45.
•• Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: the phase 2 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026–37 The ARISE Phase 3 trial of erenumab for the prevention of episodic migraines. CrossRef
46.
Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz RA, et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 2018;58:715–23.CrossRef
47.
de Hoon J, Van Hecken A, Vandermeulen C, Herbots M, Kubo Y, Lee E, et al. Phase I, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. Cephalalgia. 2018;0:1–11.
48.
Markham A. Pegvaliase: first global approval. Drugs. 2018;78:1157–61.CrossRef
49.
Reinke T. Aimovig for migraine prevention: the new kid may have trouble fitting in. Manag Care. 2018;27:10–1.PubMed
50.
Traynor K. FDA approves licensing of erenumab-aooe to prevent migraine. Am J Heal Pharm. 2018;75:929–30.
51.
Choy M. Pharmaceutical approval update. Pharm Ther. 2018;43:461–2.
52.
•• Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425–34 Excellent phase 2 randomized controlled trial demonstrating the safety and efficacy of erenumab for the treatment of chronic migraines. CrossRef
53.
Traynor J. μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend. 2011;121:173–80.CrossRef
54.
• Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. Elsevier Ltd; 2014;13:1100–1107. Excellent phase 2 trial of Eptinezumab for the prevention of frequent episodic migraine. CrossRef
55.
• Halker Singh RB, Aycardi E, Bigal ME, Loupe PS, McDonald M, Dodick DW. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: post-hoc analyses from phase 2 trials. Cephalalgia. 2018;0:1–9 A phase 2 trial of Fremanezumab for the treatment of episodic and chronic migraines.
56.
• Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine. JAMA Neurol. 2018;85054. Excellent review of Galcanezumab for the treatment of episodic migraines.
57.
Raffaelli B, Reuter U. The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics. 2018;15:324–35.CrossRef
58.
Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs. 2018;10:183–203.CrossRef
59.
Walter S, Alibhoy A, Escandon R, Bigal ME. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs. 2014;6:871–8.CrossRef
60.
Bigal ME, Walter S, Bronson M, Alibhoy A, Escandon R. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia. 2014;34:968–76.CrossRef
61.
Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia. 2014;34:483–92.CrossRef
62.
Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113–22.CrossRef
63.
Monteith D, Collins EC, Vandermeulen C, Van Hecken A, Raddad E, Scherer JC, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody LY2951742 (galcanezumab) in healthy volunteers. Front Pharmacol. 2017;8:1–11.CrossRef
Metadaten
Titel
CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review
verfasst von
Ivan Urits
Mark R. Jones
Kyle Gress
Karina Charipova
Jacob Fiocchi
Alan D. Kaye
Omar Viswanath
Publikationsdatum
01.05.2019
Verlag
Springer US
Erschienen in
Current Pain and Headache Reports / Ausgabe 5/2019
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-019-0768-y

Weitere Artikel der Ausgabe 5/2019

Current Pain and Headache Reports 5/2019 Zur Ausgabe

Uncommon and/or Unusual Headaches and Syndromes (J Ailani, Section Editor)

The Hypertensive Headache: a Review

Hot Topics in Pain and Headache (N. Rosen, Section Editor)

The Utilization of Mu-Opioid Receptor Biased Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects

Hot Topics in Pain and Headache (N Rosen, Section Editor)

Essential Elements for Enhanced Recovery After Intra-Abdominal Surgery

Other Pain (A Kaye and N Vadivelu, Section Editors)

Metabolic and the Surgical Stress Response Considerations to Improve Postoperative Recovery

Other Pain (A Kaye and N Vadivelu, Section Editors)

Perioperative Pain Management in the Critically Ill Patient

Neuropathic Pain (A Abd-Elsayed, Section Editor)

Neurogenic Claudication: a Review of Current Understanding and Treatment Options

Neu im Fachgebiet AINS

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise